Technical Analysis for SCLP - Scancell Holdings Plc

Grade Last Price % Change Price Change
A 16.50 -1.49% -0.25
SCLP closed down 0.74 percent on Thursday, September 28, 2023, on 28 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction -1.49%
Stochastic Reached Overbought Strength -1.49%
Wide Bands Range Expansion -1.49%
Overbought Stochastic Strength -1.49%
Calm After Storm Range Contraction -2.22%
NR7 Range Contraction -2.22%
Narrow Range Bar Range Contraction -2.22%
Inside Day Range Contraction -2.22%
Wide Bands Range Expansion -2.22%
Crossed Above 200 DMA Bullish -2.22%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low 6 minutes ago
Down 1% 6 minutes ago
Up 1% 6 minutes ago
Possible NR7 about 20 hours ago
Up 1% 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Scancell Holdings Plc Description

Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Medicine Pipe Cancer Branches Of Biology Clinic Medical Specialties Biopharmaceutical Therapy Clinical Trial Immunology Tumor Antibodies Immune System Monoclonal Antibodies Antibody Therapies Vaccine Lung Cancer Treatment Of Cancer Immunotherapies Cancer Therapeutics Immunotherapy Monoclonal Antibody

Is SCLP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 29.4
52 Week Low 7.588
Average Volume 908,249
200-Day Moving Average 16.13
50-Day Moving Average 11.31
20-Day Moving Average 12.45
10-Day Moving Average 15.49
Average True Range 1.10
RSI (14) 71.75
ADX 35.34
+DI 43.13
-DI 15.02
Chandelier Exit (Long, 3 ATRs) 14.99
Chandelier Exit (Short, 3 ATRs) 10.90
Upper Bollinger Bands 19.26
Lower Bollinger Band 5.63
Percent B (%b) 0.82
BandWidth 109.54
MACD Line 1.76
MACD Signal Line 1.18
MACD Histogram 0.5812
Fundamentals Value
Market Cap 136.55 Million
Num Shares 815 Million
EPS -1.50
Price-to-Earnings (P/E) Ratio -11.17
Price-to-Sales 0.00
Price-to-Book 12.26
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.39
Resistance 3 (R3) 17.42 17.23 17.28
Resistance 2 (R2) 17.23 17.07 17.22 17.25
Resistance 1 (R1) 16.99 16.97 16.90 16.96 17.21
Pivot Point 16.81 16.81 16.76 16.79 16.81
Support 1 (S1) 16.57 16.65 16.48 16.54 16.29
Support 2 (S2) 16.38 16.55 16.37 16.25
Support 3 (S3) 16.14 16.38 16.22
Support 4 (S4) 16.11